Study: NCT01258803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
Description: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI with spacer
Description: Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI with spacer
Description: Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI with spacer
Description: Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI without spacer
Description: Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI without spacer
Description: Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI without spacer
Description: Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate DPI
Description: Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate DPI
Description: Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate DPI
Description: Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate DPI
Description: Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate DPI
Description: Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate DPI
Description: Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.